Loading...
•
Sep 30, 2021
Atara Q3 2021 Earnings Report
Atara reported positive data from its pivotal Phase 3 ALLELE study, progress in regulatory submissions for Tab-cel, and durable clinical improvements with ATA188 in progressive multiple sclerosis.
Key Takeaways
Atara Biotherapeutics reported financial results for the third quarter of 2021, highlighting positive data from the Phase 3 ALLELE study for Tab-cel and progress with ATA188 for multiple sclerosis. The company is preparing for regulatory submissions and continues to advance its CAR T programs.
Positive data from the pivotal Phase 3 ALLELE study reinforces the transformative potential of Tab-cel.
Significant regulatory progress for Tab-cel with an imminent EU MAA submission and clarity on FDA requirements for BLA submission planned for Q2 2022.
ATA188 data demonstrates durable, clinically meaningful disability improvement and possible remyelination in patients with progressive multiple sclerosis.
Atara is making good progress and expects to submit an IND for ATA3219, an off-the-shelf, allogeneic CD19 CAR T immunotherapy targeting B-cell malignancies, in Q1 2022.
Forward Guidance
Atara believes that its cash as of September 30, 2021, together with the $45.0 million upfront payment received as a result of our entry into the Pierre Fabre Commercialization Agreement, is sufficient to fund planned operations into the second quarter of 2023
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...